Abstract
Epithelial ovarian cancer is a heterogeneous disease with distinct histological subtypes characterized by different patterns of clinical behaviour. The identification of molecular pathways associated with individual subtypes has fuelled enthusiasm for the development of targeted therapies directed at specific subtypes of ovarian cancer. To date, the most successful targeted therapies in ovarian cancer to have undergone clinical development include anti-angiogenic agents and PARP inhibitors. Other promising areas of development include folate receptor antagonists, MEK and BRAF inhibitors in low-grade serous carcinoma, and immunotherapy. These novel therapeutic agents have the potential to maximize tumor efficacy, minimize toxicity and improve outcomes for women with epithelial ovarian cancer.
Keywords:
Anti-angiogenic therapy; PARP inhibitor; immunotherapy; ovarian cancer; targeted therapy.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab / administration & dosage
-
Bevacizumab / adverse effects
-
Female
-
Folic Acid Antagonists / therapeutic use
-
Humans
-
Indoles / administration & dosage
-
Indoles / adverse effects
-
Molecular Targeted Therapy / methods*
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / metabolism
-
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
-
Receptor, ErbB-2 / antagonists & inhibitors
Substances
-
Angiogenesis Inhibitors
-
Folic Acid Antagonists
-
Indoles
-
Poly(ADP-ribose) Polymerase Inhibitors
-
Bevacizumab
-
ERBB2 protein, human
-
Receptor, ErbB-2
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf
-
nintedanib